fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Moves to Restrict Mass-Marketed

Swollen legs and/or ankles, generally mild and temporary in nature but reported more frequently than in other SGLT2 inhibitors like Jardiance or Farxiga ("Farxiga")

The presentation highlighted that: Weight suppression can increase eating disorder risk regardless of BMI Larger degrees of suppression are associated with greater symptom severity Weight suppression is linked to medical instability and poorer recovery outcomes Weight suppression should be understood as a clinical concern rather than a marker of success

Cancer Res 1999

M.Von JonquieresG.KarlT.DruckerD

In reality due to the kinetics of HDIVC and IV GSH there is some question regarding the time required between IV GSH and high dose IVC (or most oxidative therapies**)

Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD